Native rat hippocampal 5-HT1A receptors show constitutive activity

Molecular Pharmacology

Volumn 71, Issue 3, 2007, Pages 638-643

  Martel, Jean Claude ^a   Ormière, Anne Marie ^a   Leduc, Nathalie ^a   Assié, Marie Bernadette ^a   Cussac, Didier ^a   Newman Tancredi, Adrian ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); METITEPINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN; SEROTONIN 1A RECEPTOR; SODIUM; SPIPERONE;

ANIMAL TISSUE; ARTICLE; BRAIN MEMBRANE; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; HIPPOCAMPUS; IC 50; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT; SCINTILLATION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HIPPOCAMPUS; MALE; PIPERAZINES; PYRIDINES; RATS; RECEPTOR, SEROTONIN, 5-HT1A;

EID: 33847148112     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.029769     Document Type: Article

References (40)

1. Adan RA and Kas MJ (2003) Inverse agonism gains weight. Trends Pharmacol Sci 24:315-321.
2. 35S]GTPgammaS binding in rat hippocampal membranes. Eur J Pharmacol 343:303-312.
3. Assié MB, Cosi C, and Koek W (1999) Correlation between low/high affinity ratios for 5-HT(1A) receptors and intrinsic activity. Eur J Pharmacol 386:97-103.
4. 35S]-GTP[gamma]S binding isotherms. Neuropharmacology 40:57-64.
5. Barnes NM and Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083-1152.
6. Barr AJ and Manning DR (1997) Agonist-independent activation of Gz by the 5-hydroxytryptamine1a receptor co-expressed in Spodoptera frugiperda cells. Distinguishing inverse agonists from neutral antagonists. J Biol Chem 272:32979-32987.
7. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
8. Corradetti R, Mlinar B, Falsini C, Pugliese AM, Cilia A, Destefani C, and Testa R (2005) Differential effects of the 5-hydroxytryptamine (5-HT)1A receptor inverse agonists Rec 27/0224 and Rec 27/0074 on electrophysiological responses to 5-HT1A receptor activation in rat dorsal raphe nucleus and hippocampus in vitro. J Pharmacol Exp Ther 315:109-117.
9. 2C receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking. Mol Pharmacol 62:578-589.
10. Cussac D, Pasteau V, and Millan MJ (2004) Characterisation of Gs activation by dopamine D1 receptors using an antibody capture assay: antagonist properties of clozapine. Eur J Pharmacol 485:111-117.
11. De Deurwaerdere P, Navailles S, Berg KA, Clarke WP, and Spampinato U (2004) Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 24:3235-3241.
12. de Ligt RA, Kourounakis AP, and IJzerman AP (2000) Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery. Br J Pharmacol 130:1-12.
13. Hensler JG (2002) Differential regulation of 5-HT1A receptor-G protein interactions in brain following chronic antidepressant administration. Neuropsychopharmacology 26:565-573.
14. 2-adrenergic receptors by sodium. J Biol Chem 265:21590-21595.
15. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
16. Kenakin T (2004) Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol 65:2-11.
17. Mannoury la Cour C, El Mestikawy S, Hanoun N, Hamon M, and Lanfumey L (2006) Regional differences in the coupling of 5-HT1A receptors to G proteins in the rat brain. Mol Pharmacol 70:1013-1021.
18. McLoughlin DJ and Strange PG (2000) Mechanisms of agonism and inverse agonism at serotonin 5-HT1A receptors. J Neurochem 74:347-357.
19. Meltzer HY, Li Z, Kaneda Y, and Ichikawa J (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27:1159-1172.
20. Millan MJ (2000) Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors. J Pharmacol Exp Ther 295:853-861.
21. Milligan G (2003a) Constitutive activity and inverse agonists of g protein-coupled receptors: a current perspective. Mol Pharmacol 64:1271-1276.
22. 35S]GTPgammaS binding assays. Trends Pharmacol Sci 24:87-90.
23. Milligan G, Kellett E, Dacquet C, Dubreuil V, Jacoby E, Millan MJ, Lavielle G, and Spedding M (2001) S 14506: novel receptor coupling at 5-HT(1A) receptors. Neuropharmacology 40:334-344.
24. Morisset S, Rouleau A, Ligneau X, Gbahou F, Tardivel-Lacombe J, Stark H, Schunack W, Ganellin CR, Schwartz JC, and Arrang JM (2000) High constitutive activity of native H3 Receptors regulates histamine neurons in brain. Nature (Lond) 408:860-864.
25. Newman-Tancredi A, Assié MB, Leduc N, Ormiere AM, Danty N, and Cosi C (2005) Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol 8:341-356.
26. Newman-Tancredi A, Conte C, Chaput C, Spedding M, and Millan MJ (1997a) Inhibition of the constitutive activity of human 5-HT1A receptors by the inverse agonist, spiperone but not the neutral antagonist, WAY 100,635. Br J Pharmacol 120:737-739.
27. Newman-Tancredi A, Conte C, Chaput C, Verriele L, and Millan MJ (1997b) Agonist and inverse agonist efficacy at human recombinant serotonin 5-HT1A receptors as a function of receptor:G-protein stoichiometry. Neuropharmacology 36:451-459.
28. i3 activation: conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling. Mol Pharmacol 62:590-601.
29. Newman-Tancredi A, Cussac D, Marini L, Touzard M, and Millan MJ (2003a) h5-HT(1B) receptor-mediated constitutive Galphai3-protein activation in stably transfected chinese hamster ovary cells: an antibody capture assay reveals protean efficacy of 5-HT. Br J Pharmacol 138:1077-1084.
30. Newman-Tancredi A, Rivet JM, Cussac D, Touzard M, Chaput C, Marini L, and Millan MJ (2003b) Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924. Naunyn-Schmiedeberg's Arch Pharmacol 368:188-199.
31. Newman-Tancredi A (2003) Differential ligand efficacy at h5-HT1A receptor-coupled G-protein subtypes: a commentary. International Congress Series 1249:101-117.
32. Odagaki Y and Fuxe K (1995) Pharmacological characterization of the 5-hydroxytryptamine-1A receptor-mediated activation of high-affinity GTP hydrolysis in rat hippocampal membranes. J Pharmacol Exp Ther 274:337-344.
33. 35S]GTPgammaS binding in rat cerebral cortex. Eur J Pharmacol 521:49-58.
34. 35S]GTPgammaS binding in rat hippocampal membranes. J Pharmacol Sci 98:66-76.
35. Roberts DJ and Strange PG (2005) Mechanisms of Inverse Agonist action at D2 dopamine receptors. Br J Pharmacol 145:34-42.
36. 1b-adrenergic receptor subtypes. Mol Pharmacol 56:858-866.
37. 35S] GTPgamma[S] binding: evidence for constitutive activity of the recombinant and native rat and human H3 receptors. Br J Pharmacol 135:383-392.
38. Seifert R and Wenzel-Seifert K (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn-Schmiedeberg's Arch Pharmacol 366:381-416.
39. 35S]GTPgammaS binding. Eur J Pharmacol 320:267-275.
40. Wu S and Liu B (2005) Application of scintillation proximity assay in drug discovery. BioDrugs 19:383-392.